While cervical cancer is preventable, an estimated 14,000 new cases are diagnosed in the United States every year, leading to almost 4,300 deaths from the disease.

In this recording from the 21st International Congress of Cytology (ICC), Prof Mark Stoler shows evidence that the use of HPV DNA tests as the primary form of screening, followed by using p16/Ki-67 dual staining in triage can prove effective in identifying women who are at the highest risk of cervical cancer. This testing method gives actionable results that allows clinicians and health systems to prioritise resources for those who are in need of them.